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lines informing the use of UDM, there appears to be a general consensus among
practitioners that utilize UDMon:which patients tomonitor, how often tomonitor,
and which substances are most important to detect.
MEDICAL DEVICE/DIAGNOSTICS – Research on Methods
PMD55
PREDICTIVE ACCURACY OF METHODS FOR IDENTIFYING PATIENTS RECEIVING
PERITONEAL DIALYSIS AND HEMODIALYSIS USING HEALTH CARE
ADMINISTRATIVE DATA
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OBJECTIVES: To estimate the predictive accuracy of methods used to identify pa-
tients receiving peritoneal dialysis (PD) and hemodialysis (HD) in healthcare ad-
ministrative data. METHODS: The study population consisted of all persons aged
18-63 years with evidence of end-stage renal disease (ESRD) who were members of
a large US urban health maintenance organization between January 1, 2005 and
December 31, 2008 (“study period”). Using healthcare administrative data, we iden-
tified all those with any dialysis-related procedure or diagnosis codes; the date of
each patient’s first such encounterwas then designated as the “anchor date”. Using
only codes in healthcare administrative data within 30 days of anchor date, we
then designated each patient as either PD or HD. Medical records were then re-
viewed by trained abstractors using a 180-day window around each patient’s an-
chor date to ascertain positive predictive value (PPV) of procedure and diagnosis
codes in administrative data for receipt of PD and HD. RESULTS: We identified a
total of 233 patients with ESRD and one or more healthcare encounters with dial-
ysis-related procedure and diagnosis codes. Of these, 43 had codes suggesting
receipt of PD, and 173 had codes suggesting receipt of HD; dialysis modality could
not be determined for the remaining 17 patients. PPV of PD-related codes for iden-
tifying patients receiving PD within 30 days of anchor date was 34.9%; it was 67.4%
within both 90 days and 180 days of anchor date. PPV of HD-related codes for
identifying patients receiving HD within 30 days of anchor date was 86.7%; it was
90.8% within 90 days of anchor date, and 93.1% within 180 days of this date.
CONCLUSIONS: While HD-related procedure and diagnosis codes appear to have
relatively high predictive accuracy for identifying patients receiving HD, predictive
accuracy of the codes used to identify patients receiving PD is much lower.
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USING ADVANCED HEALTH CARE DATA ANALYTICS TO IDENTIFY AND
CHARACTERIZE CENTRAL VENOUS CATHETERIZATION EPISODES VIA
ELECTRONIC HEALTH RECORDS IN THE VETERANS AFFAIRS
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OBJECTIVES: Observational health care data are often used to study patient popu-
lations and outcomes of interest. Electronic Health Record (EHR) data provide a
granular and longitudinal look at patient care; however, much information is bur-
ied within the narrative text of clinical notes and is not typically available for
research. Diagnosis and procedure codes pose two difficulties when identifying
central venous catheter (CVC) episodes: 1) they are underused and 2) they are
associated with the encounter and not the actual CVC event. METHODS: We ap-
plied advanced healthcare data analyticswith natural language processing (NLP) to
extractmeaningful information about patient care from text clinical information in
the Veteran Affairs nationwide EHR database. The NLP was designed to help iden-
tify and characterize CVC episodes for patients with an inpatient encounter. Pa-
tients were characterized as having (a) a billing code for catheter insertion and (b)
having had a chest x-ray during an inpatient encounter where the presence of a
CVC was identified by NLP. RESULTS: 1.2M patients with an inpatient encounter
were found in the VA between January 1, 2006-December 31, 2010. Of them, 54,676
patients were identified as having at least one inpatient CVC episode using billing
codes. 119,768 additional patients were preliminarily identified via NLP, resulting
in a total of 174,444 CVC patients. CONCLUSIONS: Fifteen percent of inpatients had
a CVC placed and 69% of CVC patients were only identified via NLP. These rates are
consistentwith previously published literature. Thiswork shows thatNLP provides
an effective way to leverage rich observational data. We will use this to study
health outcomes in relation to the catheter placement and related interventions.
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NEW APPROACHES FOR GRAPHING PROBABILISTIC PATIENT-RELEVANT
HEALTH OUTCOMES: THE CASE OF RENAL DENERVATION FOR RESISTANT
HYPERTENSION
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OBJECTIVES: Probabilistic sensitivity analysis (PSA) repeatedly runs a simulation
model with randomly selected inputs to characterize the plausible distributions of
projected outcomes. In cost-effectiveness analysis, PSA results are conventionally
displayed as incremental cost-effectiveness scatter plots or cost-effectiveness ac-
ceptability curves. We explored patient-relevant health outcomes other than
QALYs and investigated approaches for displaying probabilistically generated val-
ues, using the case of catheter-based renal denervation (RDN) for resistant
hypertension. METHODS: A Markov model with 54 input distributions simulated
the impact of RDN on stroke, myocardial infarction (MI), coronary heart disease
(CHD), heart failure (HF), end-stage renal disease (ESRD), cardiovascular (CV) and
all-cause death based on the Symplicity HTN-2 RCT and the literature. We report
medians and 95% credible intervals (95% CI), defined as containing 95% of all sim-
ulation results, of 10-year relative risk reductions. One-sample t-tests and ANOVA
were used to compare posterior distributions. Additional analyses evaluated alter-
native time horizons, with values ranging from one year to lifetime. RESULTS:
Relative risk reductions over ten years (95% CI) were: stroke 31.4% (23.1; 36.0%), MI
30.0% (8.9; 38.1%), CHD 22.2% (9.0; 29.4%), HF 13.9% (11.0; 21.7%), ESRD 30.7% (28.8;
34.5%), CV death 30.3% (12.6; 35.7%), and all-cause death 14.4% (4.1; 20.1%). All
clinical outcomes were significantly different from 0% and between each other
(p0.0001). Distribution dotplots, cumulative hazard curves, and survival curves
with 95% credibility intervals were developed as graphic representations of prob-
abilistic results. CONCLUSIONS:Whilemodel-based projections suggest that cath-
eter-based renal denervation leads to clinically and statistically significant event
reductions across clinical outcomes, considerable differences exist between the
distributions of individual reductions. Graphic, probabilistic representation of pa-
tient-relevant endpoints may facilitate a deeper understanding of uncertainty as-
sociated with the long-term clinical effectiveness of new therapies. In addition to
informing clinicians and payers, the proposed conceptual approach could also
contribute to patient education and shared decision making.
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COST-EFFECTIVENESS OF APPLYING PROLONGED MECHANICAL VENTILATION
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OBJECTIVES: The conventional incremental cost-effectiveness ratio (ICER) and
cost-per-expected life in patients undergoing prolonged mechanical ventilation
(PMV), stratified by different underlying diseases, were determined. METHODS: A
nationwide sample of 50,481 patients who had received continualmechanical ven-
tilation for more than 21 days was collected during 1997-2007. After stratifying the
patients according to specific diagnoses, a latent class analysis (LCA) was per-
formed to categorize PMV patients with multiple co-morbidities into several ho-
mogeneous groups. The survival functions were estimated for individual groups
using the Kaplan-Meier method and extrapolated to 300 months through a semi-
parametricmethod. The survival functions were adjusted with a utility valuemea-
sured by EQ-5D from a convenient sample of 142 PMV patients to estimate the
quality-adjusted life expectancies (QALE). The lifetime expenditures paid by Na-
tional Health Insurance (NHI) were estimated bymultiplying the average spending
with the survival probability for different duration-to-dates and summed up for
different groups. RESULTS: The results showed that PMV therapy costs over
58,000 USD (U.S.dollars) per QALY for almost all patients with poor cognition.
For patients with partial cognition, PMV therapy costs less than 33,000 USD per
QALY for those with cancer, liver cirrhosis, intracranial or spinal cord injuries,
or multiple co-morbidities who are less than 65 years of age; it costs about
52,000-63,400 USD per QALY for those with end stage renal disease, degenera-
tive neurological diseases, or multiple co-morbidities over age 85. All costs-per-
expected life were below 38,000 USD except for those with a longer life expec-
tancy or QALE. CONCLUSIONS: The conventional ICER for PMV varies greatly
depending on the different underlying causes and co-morbidities. The mainte-
nance treatment for PMV patients with poor cognition is the least cost-effective.
The indicator of cost-per-expected life could be considered to improve fairness
in resource allocation.
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ASSESSMENT OF ADMINISTRATIVE DATA FOR EVALUATING THE SHIFTING
ACQUISITION OF CLOSTRIDIUM DIFFICILE INFECTION IN ENGLAND
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OBJECTIVES: Little is known about the acquisition of Clostridium difficile infection
(CDI) and whether it represents hospital- or community-acquired infection. The
objective of this study is to test the feasibility and value of using national hospital
admissions data from Hospital Episode Statistics to examine trends in CDI in
England.METHODS: Hospital Episode Statistics from the period 1997/98 to 2009/10
were used. Time trends were analysed using two different denominators of hospi-
tal activity: total admissions and total bed-days. We explored the impact of so-
ciodemographic factors, comorbidity and healthcare pathways on the risk of CDI.
RESULTS: CDI rates per admission and per bed-days increased from 1997/98 to
2006/07, then decreased significantly by 50% from 2008/9 and 2009/10. This pat-
tern was similar for patients regardless of probable source of infection but the
proportion of probable community-acquired CDI cases rose steadily from 7% in
1997/98 to 13% in 2009/10. CDI rates were higher among older patients (odds ratio:
65 years, 10.9), those with more comorbid conditions (odds ratio for Charlson
index: 5, 5.6), and among patients admitted as an emergency compared with
elective admissions, but no relationship was found with deprivation score.
CONCLUSIONS: Our findings support not only the falling trend in CDI found in the
national mandatory surveillance scheme from the Health Protection Agency, but a
growing proportion of CDI presenting on admission with no evidence of prior hos-
pital exposure in the previous 90 days. We suggest that these may be community-
acquired CDI cases.
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DIAGNOSIS OF APPENDICITIS
Castillo M1, Bernal AJ1, Fajardo R2
A72 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 – A 2 5 6
1Universidad de los Andes, Bogotá, Colombia, 2Fundación Santa Fe, Bogotá, Colombia
OBJECTIVES: Diagnosing Appendicitis is a difficult challenge for emergency de-
partments. Appendicitis has been the subject of numerous investigations, but a
diagnostic tool of quality and applicability in the clinical routine has not yet been
identified. We constructed a clinical predictive model for Appendicitis using a
Bayesian network, using a decision analysis approach. METHODS:We designed a
methodology for the construction of decision models to support the process of
clinical diagnosis, which was applied specifically to the diagnosis of Appendicitis.
The methodology starts with a multiple correspondence analysis (MCA) for the
selected variables with the highest power of discrimination, based on which an
initial Bayesian network is proposed. This network was refined with the support of
a group of medical experts in the diagnosis, to define the final structure of the
Bayesian network. Finally, the model is validated through cross-validation
method. For validation we used Sanabria, Bermudez, Dominguez and Serna’s
(2007) database, which consists of 349 patients with suspected Appendicitis.
RESULTS: The implementation of the methodology produced results in a Bayesian
network that included eleven variables associated to signs, symptoms and labora-
tory results. The results of the proposedmodel, with respect tomedical assessment
without specialized tools for diagnosis, showed significant improvements in accu-
racy, from 81% to 94%; in sensitivity, from 85% to 98%; and in specificity, from 76%
to 90%. CONCLUSIONS: The Bayesian network constructed based on the MCA im-
proved the accuracy of Appendicitis diagnosis in comparison to othermodels avail-
able in the literature, among which are the Alvarado score and the Fenÿo score.
Additionally, the constructed Bayesian network has characteristics that facilitate
its applicability in the clinical routine.
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EVALUATING THE USABILITY OF AN EPRO DIARY FOR MEASURING COPD
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OBJECTIVES: To evaluate the usability of an electronic patient-reported outcome
(ePRO) diary in accordancewith recommendations for usability testing in the ISPOR
ePROTask Force Report.METHODS: TheNighttime Symptoms of COPD Instrument
(NiSCI) and Early Morning Symptoms of COPD Instrument (EMSCI) were pro-
grammed into a handheld device (HTC HD2®). The device and instructions [Quick
Reference Guide (QRG)] were evaluated in two rounds of testing. Each round con-
sisted of user acceptance testing (UAT) by researchers, followed by usability assess-
ment by COPD patients. Patients were trained to use the device and completed the
diary five to seven days at home, followed by a qualitative interview in the clinic
about the device’s usability. Time and duration of diary completion were recorded
on the device each day. At the interview, participants also completed a Device
Usability Questionnaire and answered questions regarding their background and
technology proficiency. RESULTS: Mean age of the sample (N15) was 60 years,
(range 40–87); 60% were male. All participants were diagnosed with COPD and
experienced symptoms at night or earlymorning, per inclusion criteria. Nine (60%)
reported being “moderately technically proficient”. Feedback from the first round
(n5) informed the refinement of screen layout, skip patterns, and QRG, before a
second round of interviews. Results from the second round (n10) confirmed ‘pop-
up’ message wording, readability, screen clarity, and comprehension. Of 15 partic-
ipants, 66.7% found the device “very easy” to learn and 73.3% rated overall use “very
easy.” Participants averaged 3.5 minutes for diary completion; completion time
decreased over time. CONCLUSIONS: This usability study confirmed that COPD
patients found the electronic, HTC HD2®-based NiSCI and EMSCI patient-friendly,
easy to use, and suitable for daily assessment of COPD symptoms.
PMD62
A SIMULATED CONTROL GROUP COMPARATIVE APPROACH TO USING PHASE I
TRIAL DATA TO ASSESS THE OUTCOMES OF A NOVEL TREATMENT FOR ACUTE
KIDNEY FAILURE
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OBJECTIVES: To develop a simulated “control” group to compare Phase 1 trial data
from acute kidney failure (AKF) patients receiving novel renal-replacement ther-
apy (RRT) with a Selective Cytopheretic Device (SCD), and to compare clinical out-
comes and economic impact of SCD treatment to hemodialysis.METHODS: Clini-
cians collected data on the first 35 patients treated with the SCD. To add a second
interventional trial arm, the developer needed a simulated control group (control)
for comparative purposes. Data from the literature and 2009 MEDPAR files were
utilized to develop a control with clinical characteristicsmatching those of the trial
population but undergoing hemodialysis. Critically, cohorts were matched on di-
agnosis, SOFA score,mechanical ventilation, sepsis, and RRT treatment. Secondary
sources contained mortality data, survivor RRT dependency, and resource con-
sumption units for the control – variables captured for trial patients. Unit resource
costs for trial patients were based on MedPAR data and the literature. SCD costs
were manufacturer-supplied. We computed relative resource cost impact for both
cohorts from imputed units and unit costs. RESULTS: Our methods yielded suffi-
cient information to compare clinical outcomes and budget impact of SCD treat-
ment relative to hemodialysis. SCD-treated patients showed 60-daymortality rates
of 31% versus control rates 50%. Savings from reduced ALOS in trial patients
exceeded incremental costs of SCD treatment. We estimated future payer budget
impact using USRDS (2010) treatment costs for survivors in both groups with con-
tinuing RRT needs progressing to ESRD care. Results showed cost avoidance of
$2.0M for 100 AKF patients. Confidence in the model was supported by sensitiv-
ities to ICU ALOS and survival rates, non-estimated variables for both cohorts. The
model withstood key variable manipulation of 20% before conclusions changed
directionally. CONCLUSIONS: A simulated control approach is a cost-effective
means for small manufacturers to conduct early hypothesis testing and build a
foundation for later-stage development.
SURGERY – Clinical Outcomes Studies
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ADVERSE EVENTS COMMONLY ASSOCIATED WITH OPIOID USE: IMPACT UPON
LENGTH OF STAY FOLLOWING SURGICAL PROCEDURE
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OBJECTIVES: The objective of this study was to determine the impact of adverse
events common to opiate use upon post-operative length of stay. METHODS: The
study was based in Cardiff and the Vale of Glamorgan in 2004. All admissions
involving a surgical procedure, other than those specifically relating to the gastro-
intestinal system, were extracted and those for patients with a secondary diagno-
sis of either constipation (ICD-10 K59), nausea and vomiting (R11), pruritus (L29),
headache (R51), dizziness (R42) or fever of unknown origin (R50) were flagged.
These cases werematched by age (5 year age banded) and sex to controls admitted
with the same procedure (defined by three character OPCS-4 code). Length of stay
for cases versus controls was compared using the Wilcoxon rank signed test.
RESULTS: Of 116,309 hospital episodes, 58,025 included a surgical procedure. Of
these 285 included one of the diagnoses listed above of which 234 (82.1%) could be
matchedwith an age and sex control. Mean age of subjects was 53.7 (sd 23.5) and 96
(41.%) were male. Overall length of stay was greater for cases (median  11.0 days
[IQR 6.0-20.25] versus controls (5.0 days [1.0-14.0] p0.001. This was true for most
subgroups: constipation 14.5 days [7-23.25] versus 6 days [2-19] p 0.001; nausea
and vomiting 14 days [6-22.25] versus 7 days [1-19.25] p0.001; pruritus 5 days
[3-12] versus 1 days [1-3] p0.027; headache 13 days [6-39.5] versus 1.5 days [0-6.25]
p0.011 and fever 8 days [4.5-12.5] versus 1 days [0-8] p0.011. There was no
significant difference for dizziness 8 days [1.75-13.5] versus 2 days [0-10.5] p0.229.
CONCLUSIONS: This study demonstrates that adverse events commonly associ-
ated with opioid use have a significant impact on post-operative length of stay.
Reducing these events could have benefits both in terms of the well-being of the
individual patient and overall healthcare costs.
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RELATIONSHIP BETWEEN MEDICAL CO-MORBIDITIES AND HOSPITALIZATION
FOLLOWING ELECTIVE TOTAL KNEE ARTHROPLASTY (TKA)
Kirkness CS1, Peters CL2, Fritz JM2
1University of Illinois at Peoria, Peoria, IL, USA, 2University of Utah, Salt Lake City, UT, USA
OBJECTIVES: Demand for a primary TKA is increasing and projected to grow expo-
nentially by 2030. Comorbidities have been identified as a contributor to increased
postoperative length of the stay (LOS) of the patient in the hospital, a major con-
tributor to the cost of TKA. The purpose of the study is to assess the effect of
comorbidities [diabetes, hypertension, obesity (bmi 30 kg/m2), chronic back
pain(CBP), insomnia, cancer, osteoporosis], on patient LOS after elective TKA.
METHODS: Patients 40 years old with a primary unilateral TKA, excluding those
with a 2nd TKA surgery within the year, were retrospectively extracted from a
clinical orthopedic database between September 1, 2008 to November 30, 2010. LOS
and comorbidities were obtained by chart abstraction from the electronic medical
record. Unadjusted and adjusted odds ratios (OR) of having a LOS 3 days were
calculated for each comorbidity. Using logistic regression analysis, ORs were ad-
justed for age, gender, pre-operative physical/mental health and preoperative level
of physical activity. RESULTS:A total of 174 patientswith an average age of 63.8 (SD
10.2, 41-85) years were included in the study; 63% (110) were female and 56% (98)
were obese. 75% of the patient population was discharged in 3 days. Unadjusted
analysis identified those with diabetes, hypertension, obesity, CBP, cancer and
osteoporosis as being more likely to have a LOS 3 than those without these co-
morbidities. In adjustedORs, the likelihood of having a LOS3 dayswere 7.88 times
(95% confidence interval[CI]2.28-27.21) among patients with osteoporosis and
1.87 times (95% CI1.20-9.96) among patients with a history of cancer versus those
without these comorbidities. CONCLUSIONS: Few studies have focused on specific
comorbidities that influence LOS. We found that preoperative diagnosis of osteo-
porosis or cancer increased the LOS following elective TKA. Previous determinants,
age, gender, pre-operative level of physical activity, preoperative and physical
health were not influential.
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ANALYSIS OF BARIATRIC OUTCOMES LONGITUDINAL DATABASE (BOLD) TO
PREDICT PERCENT BMI LOSS AFTER BARIATRIC SURGERY
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OBJECTIVES: The objective of this study was to utilize the BOLD database to ana-
lyze percent BMI loss after bariatric surgery. Of particular interest was the deter-
mination of predictors to help explain the large variation in bariatric surgery
success.METHODS: The dataset extracted for analysis consisted of patients age 21
or older having their first bariatric surgery (laparoscopic adjustable gastric band
(LAGB), Roux-en-y gastric bypass (RYGB), or vertical sleeve gastrectomy (VSG)) be-
tween January 1, 2007 and February 26, 2010, with pre-surgery BMI of at least 30, a
baseline visit and at least one postoperative visit. Subpopulations with postopera-
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